Stifel analyst Stephen Willey lowered the firm’s price target on Vor Bio to $16 from $17 and keeps a Buy rating on the shares following its Q4 earnings and corporate update. The recent disclosure of "encouraging" proof-of-concept data from the P1 VBP101 trial serves as a "significant de-risking event" for the asset and platform, the analyst tells investors. Further, the firm expects a number of incremental updates from this trial throughout FY23 to serve as a tailwind for the stock.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VOR:
- Vor Bio price target lowered to $22 from $38 at Baird
- Vor Bio price target lowered to $17.50 from $20 at H.C. Wainwright
- Vor Bio reports Q4 EPS (53c), consensus (60c)
- Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
- Vor Bio to Participate in Upcoming Investor Conferences